Research and Pipeline Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
Study demonstrates statistically significant and clinically relevant reduction in annualized bleeding rate compared to prophylaxis and on-demand intravenous regimens
Marstacimab, if approved, has the potential to become the first once-weekly...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Bleeding | Clinical Trials | Haemophilia | Hemophilia | Pfizer | Pharmaceuticals | Statistics | Study